Eikon Therapeutics, Inc. Common Stock (EIKN)vsRevolution Medicines Inc (RVMD)
EIKN
Eikon Therapeutics, Inc. Common Stock
$9.60
-11.03%
HEALTHCARE · Cap: $485.08M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. EIKN earns a higher WallStSmart Score of 32/100 (F).
EIKN
Avoid32
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EIKN
The strongest argument for EIKN centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : EIKN
The primary concerns for EIKN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
EIKN is growing revenue faster at 0.0% — sustainability is the question.
EIKN generates stronger free cash flow (-90M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EIKN scores higher overall (32/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eikon Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Eikon Therapeutics, Inc., is a clinical biopharmaceutical company in the United States. The company is headquartered in Millbrae, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?